Objective: Cytomegalovirus (CMV) is a ubiquitous herpes virus that persists in the host in a latent state following primary infection. We have recently observed that CMV reactivates in lungs of critically ill surgical patients and that this reactivation can be triggered by bacterial sepsis. Although CMV is a known pathogen in immunosuppressed transplant patients, it is unknown whether reactivated CMV is a pathogen in immunocompetent hosts. Using an animal model of latency/reactivation, we studied the pathobiology of CMV reactivation in the immunocompetent host.
H uman cytomegalovirus (HCMV) has been recognized as a pathogen for many years in immunosuppressed patients and until the advent of effective antiviral therapy was a lifethreatening complication of transplantation (1) . Like other ␤ herpes viruses, HCMV becomes latent following primary infection, lying dormant until some stimulus causes reactivation. Latency is the viral state in which complete viral genomes reside in host cells, without production of intact infectious virions. Following an adequate stimulus, latent viral genes can reactivate and produce infectious virus. Although HCMV is well recognized as a pathogen in immunosuppressed patients, it has garnered little attention in immunocompetent patients because of its believed benign course.
Recent work has shown that high percentages of nonimmunosuppressed critically ill surgical patients previously in-fected with HCMV are susceptible to HCMV reactivation during their critical illness and that HCMV may not be as benign as once believed (2) (3) (4) (5) . Our work and that of others has shown that reactivation of HCMV can occur in the lungs (2, 3, 6 -8) , which are known to be a reservoir for latent HCMV (9) . Pulmonary HCMV has been associated with increased duration of mechanical ventilation (3, 6, 10) as well as increased length of hospitalization (3, 6, 10) and possibly increased mortality rate (2, 4) . Because of inherent limitations in human subjects, very little is known about the pathobiology of HCMV in critically ill surgical patients.
Because there are no adequate in vitro models, we used a well-described in vivo model of murine CMV (MCMV) to study reactivation (11) (12) (13) . MCMV has been well characterized and is very similar to HCMV (14, 15) . Using a susceptible BALB/c mouse strain, intraperitoneal inoculation of MCMV causes acute infection, with subsequent development of latency in host tissues (13, 15) . Like its HCMV counterpart, MCMV has been shown to develop latency in many organs, including lung tissue (15) (16) (17) (18) . We have recently published a model of reactivation from latency using bacterial sepsis as a trigger (13) . This model affords a unique opportunity to study reactivation of CMV, and its pathologic consequences, in lungs of previously immunocompetent hosts.
This study was undertaken to evaluate the effects of CMV reactivation on cytokine/chemokine expression in the lungs of previously immunocompetent hosts. Furthermore, the effects of antiviral therapy on both viral reactivation and cytokine/chemokine expression were studied. Finally, the effect of CMV reactivation on pulmonary fibrosis was evaluated using novel computer image analysis techniques. We present data herein suggesting that local tissue cytokine expression in hosts latently infected with CMV is abnormally up-regulated following CMV reactivation and that this causes pathology in the previously immunocompetent host.
METHODS
Animals, Viral Infection, and Confirmation of Latency. Female BALB/c mice (Harlan, Indianapolis, IN) 6 -8 wks of age were used in this study. Purified Smith strain (VR-194/ 1981) murine CMV was obtained from ATCC (Rockville, MD). Primary CMV infection was achieved by intraperitoneal injection of 2 ϫ 10 4 PFU Smith strain MCMV. Following MCMV infection, a cohort of five mice were killed at 16 wks to confirm latent MCMV infection. Mice were killed by cervical dislocation under inhalation anesthesia. Mouse lungs and salivary gland were dissected aseptically and frozen immediately in liquid nitrogen and then stored at Ϫ80°C. Tissue samples were evaluated by polymerase chain reaction (PCR) and reverse transcription (RT)-PCR to confirm primary infection and latency/reactivation, respectively. As previously published, we define latency as having viral DNA present in host tissues, without transcription of viral genes (13, (17) (18) (19) (20) . This differs somewhat from the definition used in human studies, which often rely on demonstration of live virus by culture, or worse yet by immunoglobulin status, since tissue biopsies often are not possible.
All mice were housed in a large animal facility, isolated from other mice, adhering to the Guide for the Care and Use of Laboratory Animals (20) following protocol approval by our Institutional Review Board.
CMV Reactivation. We have previously published that an LD 50 model of cecal ligation and puncture (CLP) will stimulate pulmonary reactivation of latent MCMV in 100% of surviving mice (13) . Reactivation is not isolated to lungs, also occurring in liver, spleen, and salivary glands (unpublished data). As previously described, reactivation from latency is defined as having messenger RNA (mRNA) transcription of later viral genes (13, (17) (18) (19) 21) (for a review, see Ref. 22 ). Viral mRNA becomes detectable between 7 and 14 days following CLP with this model, with peak viral mRNA transcription occurring 21 days after CLP (13) .
For these experiments, mice underwent CLP via laparotomy under general anesthesia slightly modified from that previously described by Baker et al. (23) . Briefly, through a lower midline incision, the cecum was delivered, ligated with a silk suture 1 cm from the tip, and singly punctured with a 23-gauge needle. The laparotomy was closed with running monofilament suture.
Three groups underwent CLP for these experiments: The first cohort (CMVϩ, n ϭ 45) was latently infected with MCMV. Following CLP, groups of surviving CMVϩ mice (3) (4) (5) were killed at 1, 2, 3, 7, 14, and 21 days after CLP (n ϭ 3, 3, 4, 5, 4, and 5, respectively). As controls, a second cohort of healthy mice underwent CLP (CMVϪ, n ϭ 24), and pairs of surviving CMVϪ mice were killed at 1, 2, 3, 7, 14, and 21 days after CLP. Finally, a third cohort was latently infected with MCMV, underwent CLP, and received daily treatment with ganciclovir (10 mg/kg/day subcutaneously) beginning the day after CLP (CMVϩGCV, n ϭ 30). Cohorts of surviving CMVϩGCV mice were killed at 7, 14, and 21 days after CLP (n ϭ 4, 5, and 5, respectively).
Ganciclovir dosing of 10 mg/kg/day (in 0.2 mL of saline vehicle) was chosen because this has been shown to be efficacious in mice (24, 25) . This is also a standard dose in adults for CMV disease. Saline-injected controls for the GCV experiment were not done because previous work by us has shown that neither sham surgery (13) nor saline injection (unpublished data) is sufficient to influence reactivation. For all groups, following death, lung tissues were evaluated for viral reactivation and inflammatory mediator expression using PCR and RT-PCR. Tissue samples were also fixed in formalin and paraffin embedded for histologic analyses.
PCR, RT-PCR, and Nested PCR. All PCR and RT-PCR reactions for transcription of MCMV immediate early-1, MCMV glycoprotein B (GB), and ␤-actin genes were performed using previously published primers (13) . Tumor necrosis factor (TNF)-␣ and interleukin (IL)-1␤ primer sets were obtained from Stratagene. Primers for neutrophil chemokine KC (KC) and macrophage inflammatory protein (MIP)-2 were synthesized using sequences described previously by Salkowski et al. (26) .
DNA was extracted from tissues using QIAamp Tissue Kit (QIAGEN GmbH, Hilden, Germany). DNA extracted from tissue homogenates was eluted in 100 L of distilled water and stored at Ϫ20°C until analysis. DNA was amplified in a total volume of 25 L with 200 nM of each primer and 1.0 units of Taq DNA polymerase (GIBCO BRL, Carlsbad CA) added to 2.5 L of a PCR buffer (50 mM KCl, 20 mM Tris-HCl [pH 8.4], and 1.5 mM MgCl 2 ). PCR reactions were carried out using a Perkins Elmer 9700 thermocycler (PE Applied Biosystems, Foster City, CA), using the following program: initial denaturation 4 mins at 94°C, 35 cycles denaturation 30 secs at 94°C, annealing 30 secs at 53°C, elongation 30 secs at 72°C, final elongation 7 mins at 72°C, then hold at 4°C. ␤-actin transcripts were used as a cellular transcript control. Amplification products were separated by electrophoresis in 1% agarose gels, and gels were stained with ethidium bromide.
RNA was extracted from tissues using TRIzol Reagent (GIBCO BRL, Carlsbad CA), dissolved in 100 L of DEPT water, and stored at Ϫ80°C. Reverse transcription reactions were carried out using 1-5 g of RNA digested with 1 units of DNase I (GIBCO BRL) at 37°C for 20 mins. The RT reaction was performed in a total volume of 20 L, containing 60 mM KCl, 15 mM Tris-HCl (pH 8.4), 3 mM MgCl 2 , 10 mM dithiothreitol, 20% (vol/vol) glycerol, 1 mM each deoxynucleoside triphosphate, 12.5 pM random primer (GIBCO BRL), and 2.5 units Super-transcriptase (GIBCO BRL). Primer annealing was done for 10 mins at 25°C, and RT was carried out for 30 mins at 42°C, then digestion with 1 unit of RNAseH, followed by denaturation for 5 mins at 95°C. To control for DNA contamination, every sample had a concomitant parallel experiment with no RT reaction.
Following RT reactions, 2 L of the resulting complementary DNA was amplified using the same conditions as outlined for PCR reactions. If this first reaction yielded no visible product, a second (nested) PCR was performed using 1 L of this first PCR reaction product. Estimated sensitivity for CMV detection is 10 -100 copies (unpublished data).
Quantitative Real Time PCR and RT PCR. Primer sets and fluorescence resonance energy transfer type probes were designed and optimized for MCMV GB, TNF-␣, and ␤-actin genes. Plasmids homologous to the sequences amplified by our PCR primers were cloned for these genes, and using serial dilution of known plasmid concentrations, standard curves were constructed for quantitation. Regression equations had very high R 2 values (95% ␤-actin, 96% TNF, and 99% GB) and were used for subsequent copy number calculations. Real-time PCR results are expressed as copies of DNA/mRNA per copies of ␤-actin. All samples were analyzed in duplicate, and results are expressed as mean copies Ϯ SE.
Sequences for real-time primers/probes designed are as follows: TNF-␣, ␤-actin, CMV GB.
Image Analysis for Fibrosis. Lung tissues from latently infected (CMVϩ), noninfected (CMVϪ), and latently infected ganciclovirtreated (CMVϩGCV) mice were obtained 3 wks after CLP. Lung tissues were fixed, sectioned, and stained with trichrome to identify the presence of mature collagen and fibrosis. Using computer image analysis techniques (detailed subsequently), ten random areas of interest were imaged and image segmentation was performed. Examples are shown in Figure  1 . The surface areas of the segmented images were calculated with image analysis software for the four segmented colors (fibrosis, blank space, cytoplasm, or nuclei). Following quantitation of fibrosis, comparisons were performed between mice with reactivated CMV (CMVϩ), mice without (CMVϪ), and latently infected mice with reactivation blocked (CMVϩGCV). Our image analysis technician was blinded to all study groups to prevent bias.
Specifically, slides were imaged using a Hitachi HV-C20-SA 3CCD color camera mounted on an Olympus BX-51 research microscope. The microscope had a Prior H101 precision motorized stage driven by a ProScan advanced stage controller. The camera and stage were controlled via the Image-Pro Plus software. Imaging tissue sections were automated using an Image-Pro Plus macro calibrated for each microscope objective. Initial objective measurement calibration was accomplished using a precision 0.01-mm stage micrometer, saving the calibration settings within the macro to facilitate batch processing. Once the slide was placed on the stage, the proper objective was selected, stage travel limits were set, and focus was adjusted. The macro captured 640 ϫ 480 pixel blocks within the stage travel limits to build a completed full color image. Images were acquired using Media Cybernetics Image-Pro Plus version 4.5 on a Dell OptiPlex GX400 computer with Windows 2000 Pro operating system. Following image segmentation, fibrosis (represented as blue on trichrome, segmented to green; Figure 1) was quantitated. Percent area and integrated optical density were averaged for each slide across all areas of interest (AOIs), and standard deviations were calculated. Area in mm 2 , percent area, and integrated optical density were used to compare the amount of fibrosis for each experimental group. Images were stored as uncompressed jpeg or TIF files. Tissue features from selected AOIs were analyzed for number of objects, percent of objects, percent area, and integrated optical density. Five to ten AOIs were selected from each large image randomly using a macro to capture a series of 640 ϫ 480 pixel blocks. Areas of interest were selected from a specific tissue section, on each slide, with the position of the tissue section recorded as counted from the slide label. Similar sections were then analyzed on each subsequent slide. Areas of interest were captured at 48-bit pixel depth and the images saved for analysis. Each selected tissue feature was assigned a unique color (segmentation) using the hue, saturation, and intensity (HSI) color model. Segmentation allowed individual features to be separated from background noise before analysis. Data were exported to Microsoft Excel (Microsoft, Redmond, WA) for analysis.
Statistical Analyses. Statistical analyses including Kruskal-Wallis test (nonparametric analysis of variance), two-tailed Student's ttest, Mann-Whitney-Wilcoxon test, and Fisher's exact test were performed where appropriate. For quantitative TNF-␣ data, a log transformation was used to symmetrize the distributions and, more important, stabilize the variances for each group-time batch, so that these variances no longer increased with mean values. Robust estimates of the standard deviations for technical and biological variability were .72 and .51, respectively, indicating the importance of replication. We considered p Ͻ .05 as significant for all testing. Means are expressed as mean Ϯ SD. Statistical software used was Excel (Microsoft) and S-Plus 7.0 (Insightful Corporation).
RESULTS
CLP Caused Pulmonary MCMV Reactivation. Cecal ligation and puncture caused detectable pulmonary reactivation of latent MCMV between day 7 and 14 in CMVϩ mice, which is consistent with our previously published results (13) (Fig. 2) . There was no MCMV mRNA expression in noninfected healthy mice undergoing CLP (CMVϪ, data not shown). Overall survival following CLP was not significantly different between groups (53% CMVϩ, 50% CMVϪ, and 47% GCV-CMVϩ mice), which is also consistent with our previously published results (13) .
MCMV Reactivation Caused Prolonged Pulmonary Inflammation. Lung tissue expression of cytokines and chemokines has been well characterized following CLP and endotoxemia. Numerous inflammatory cytokines/chemokines are induced by either stimulus, including TNF-␣, IL-1␤, chemokine KC, and MIP-2 (27) (28) (29) . Our results from noninfected healthy CMVϪ control mice undergoing CLP corroborate those previously published by other investigators. There was transcription of pulmonary TNF-␣, IL-1␤, KC, and MIP-2 mRNA occurring 24 -72 hrs after CLP, which became undetectable by day 7 after CLP (Fig. 3 ). Similar to normal controls, CLP caused early pulmonary transcription of cytokine/chemokine mRNA in mice latently infected with MCMV ( Fig. 4 ). However, in contrast to controls, latently infected mice had prolonged pulmonary expression of these inflammatory mediator mR-NAs, which persisted for 3 wks after CLP and MCMV reactivation. Prolonged pulmonary inflammation following bacterial sepsis and MCMV reactivation suggest a possible mechanism of pathology for reactivated MCMV.
Ganciclovir Prevented Pulmonary MCMV Reactivation. To test the hypothesis that MCMV reactivation triggered by bacterial sepsis can be blocked by ganciclovir, latently infected mice were treated prophylactically with ganciclovir (10 mg/ kg/day subcutaneously) after CLP (CMVϩGCV). Our previous experience has shown that MCMV replication occurs maximally 3 wks after CLP reactivation (13) ; therefore, the cohort was analyzed for signs of reactivation at this time point. Nested RT-PCR showed no viral transcription (Fig. 5) , indicating that administration of ganciclovir after CLP blocked reactivation of latent MCMV induced by bacterial sepsis.
Blocking MCMV Reactivation Prevented Prolonged Pulmonary Inflammation. To further evaluate the abnormal pulmonary cytokine/chemokine expression seen in mice following CLP and MCMV reactivation, quantitative real time RT-PCR was used. Specifically, pulmonary TNF-␣ mRNA transcription was quantitated at the various time points after CLP for mice latently infected with CMV (CMVϩ), non-CMV-infected controls (CMVϪ), and ganciclovir-treated CMVϩ mice (CMVϩGCV).In CMVϪ control mice, there was a normal TNF-␣ transcriptional response to CLP, with TNF-␣ mRNA levels peaking at day 1, decreasing by day 2, and returning to baseline for the remaining 3 wks (Fig. 6,  top) . In contrast, CMVϩ mice undergoing CLP had an initial TNF-␣ mRNA response that was prolonged for 3 days, compared with only 1 day in CMVϪ mice. TNF-␣ expression in latently infected mice (CMVϩ) and then returned to baseline by day 7 after CLP; however, at day 14 levels began to rise until becoming significantly elevated again by day 21 after CLP (Fig. 6, top) . Interestingly, reactivation of latent MCMV occurred in all CMVϩ mice before this late rise in TNF-␣ expression, between days 7 and 14 after CLP.
These findings suggested a possible pathogenic role of CMV during critical illness. If CMV reactivation in the lungs is proinflammatory, then CMV reactivation could in fact worsen or prolong ongoing Figure 6 , bottom, shows that when CMV reactivation was blocked, TNF-␣ mRNA expression was not significantly different from noninfected controls. We therefore conclude that CMV reactivation is related to increased inflammation in pulmonary tissues.
CMV Reactivation Caused Pulmonary Injury. TNF-␣, through secondary release of TGF-␤, platelet derived growth factor (PDGF)-␣, and PDGF-␤, has been causally linked to pathologic changes known as interstitial pulmonary fibrosis (30, 31) . We therefore hypothesized that the elevated TNF-␣ mRNA transcription seen following viral reactivation may be injurious, causing increased fibrosis after MCMV reactivation. Figure 7 shows that there was a significant increase in pulmonary fibrosis in latently infected CMVϩ mice when compared with CMVϪ controls after stimulation with bacterial sepsis. Treatment with ganciclovir (CMVϩGCV) after CLP in latently infected mice completely abrogated this increase in fibrosis.There was slightly less fibrosis in CMVϩGCV mice compared with CMV-CLP controls (Fig. 7) , suggesting that GCV may have anti-inflammatory effects and that the lack of fibrosis in CMVϩGCV mice might not be due to prevention of CMV reactivation. To test this hypothesis, a cohort of normal mice (n ϭ 14) underwent CLP. Half received ganciclovir 10 mg/kg/day subcutaneously subsequent to CLP, and half received saline as controls. There was no significant difference in survival between the groups (data not shown). Furthermore, image analysis showed no significant difference in pulmonary fibrosis between these groups, confirming that GCV does not have anti-inflammatory properties after CLP (data not shown). Taking these findings together, we conclude that sepsis triggered CMV-reactivation causes pulmonary fibrosis.
DISCUSSION
This study showed that CMV reactivation caused abnormal pulmonary cytokine/chemokine expression and suggests further that CMV reactivation may cause pathology in the immunocompetent host. Although we have recognized for many years that CMV can reactivate during critical illness, it is has been unclear whether these viral reactivations represent pathologic processes or are simply surrogates of severe illness. HCMV is recognized as a pathogen in immunosuppressed patients, and despite modern antiviral therapies, HCMV still causes Figure 6 . Top, comparison of pulmonary tumor necrosis factor (TNF)-␣ messenger RNA (mRNA) expression following cecal ligation and puncture (CLP) in mice latently infected with murine cytomegalovirus (CMVϩ) vs. healthy controls (CMVϪ). Mice underwent CLP, and lung tissue homogenates were evaluated at 0, 1, 2, 3, 7, 14, and 21 days for TNF-␣ mRNA using real-time polymerase chain reaction (PCR). Error bars were formed to indicate a multiple comparison adjusted p value of .05 between groups at any time point where there is no overlap. CMVϪ mice showed normal TNF-␣ mRNA expression, which peaked at day 1 and returned back toward baseline levels by days 2-3 after CLP. In contrast, CMVϩ mice had persistence of this day 1 peak in TNF-␣ mRNA expression for 3 days before returning toward baseline, showing a second elevation at day 21 after murine cytomegalovirus reactivation. Bottom, comparison of late pulmonary TNF-␣ mRNA expression following CLP in mice latently infected with MCMV treated with ganciclovir (CMVϩGCV), latent MCMV (CMVϩ), and healthy controls (CMVϪ). Mice underwent CLP, and lung tissue homogenates were evaluated at 7, 14, and 21 days for TNF-␣ mRNA using real time PCR. Error bars were formed to indicate a multiple comparison adjusted p value of .05 between groups at any time point where there is no overlap. Treatment with GCV prevented CMV reactivation in CMVϩGCV mice (see Results), and CMVϩGCV mice showed TNF-␣ mRNA expression that was not significantly different from CMVϪ mice. significant morbidity in this population. It is intriguing that a ubiquitous herpes family virus such as CMV may reactivate during critical illness, modulating or contributing to organ failure, which eventually kills so many critically ill surgical patients.
These studies were performed to determine the effects of viral reactivation in previously immunocompetent hosts. We have chosen the nomenclature "immunocompetent host," understanding that during critical illness, and particularly during intra-abdominal sepsis, host immune function may be transiently altered (32) (33) (34) (35) . This nomenclature was specifically chosen to distinguish these hosts from those with underlying chronic immunosuppressive conditions, such as AIDS or transplant patients. Although the pathologic effects of CMV reactivation in chronically immunosuppressed patients are well known, little is known about the pathobiology of CMV reactivation in hosts that were immunocompetent before their critical illness.
Our results support the hypothesis that MCMV reactivation following bacterial sepsis causes abnormal pulmonary expression of inflammatory cytokines/ chemokines. Bacterial sepsis is known to induce pulmonary expression of TNF-␣, IL-1␤, chemokine KC, and MIP-2 in healthy mice, but this expression is selflimited, returning to baseline after 2-3 days (27) (28) (29) . These previously published results are confirmed in this study (Fig.  3) . In contrast, qualitative PCR analyses of CMVϩ mice undergoing CLP show a prolonged pulmonary expression of TNF-␣, IL-1␤, chemokine KC, and MIP-2 mRNA, which persists Ն3 wks after CLPinduced bacterial sepsis (Fig. 4) . These results suggested that MCMV reactivation could contribute to or modulate pulmonary inflammation after sepsis.
To further analyze this difference, we used real-time RT-PCR to quantitate pulmonary TNF-␣ mRNA expression. There appear to be at least two significant differences in pulmonary TNF-␣ mRNA expression in CMVϩ hosts undergoing reactivation. First, there is a very prominent exaggeration in the initial TNF-␣ mRNA response (Fig. 6, top) following CLP in CMVϩ mice. This initial surge of TNF-␣ mRNA persists for 3 days after CLP in lungs of CMVϩ mice, whereas in CMVϪ mice, it rather abruptly returns to normal. One possible explanation for this is that there are higher numbers of immune cells in the organs of latently infected hosts. Podlech et al. (36) previously showed that there is a lifelong persistence of CD8 T cells in pulmonary tissues after clearance of acute MCMV infections, and we suspect that these T cells may be responsible for the initial exaggeration in TNF-␣ mRNA expression. In addition, CMV is known to stochastically attempt reactivation; however, the presence of a healthy immune system usually prevents this from going to completion (37) . Nonetheless, these stochastic attempts at reactivation may lead to further immune cells being recruited into the area, which might exaggerate an initial inflammatory response. Studies to further elucidate the source of this initial surge in TNF-␣ mRNA expression are currently ongoing.
The second major difference in pulmonary TNF-␣ mRNA expression in CMVϩ hosts undergoing CLP occurs after CMV becomes reactivated, when pulmonary TNF-␣ mRNA levels again become elevated above normal. This second elevation of tissue TNF-␣ mRNA expression may represent a natural host immune response to CMV reactivation in the lungs. This immune response may be mobilized to control the virus but in so doing may cause end organ injury by proximity. Another explanation is that CMV might be directly modulating tissue cytokine expression. Certain CMV transcripts are known to effect and/or modulate expression of inflammatory mediators, including TNF-␣, IL-1␤, nuclear factor-B, and chemokine IL-8, among others (38 -45) . Interestingly, these are many of the same mediators that have been shown to be stimulatory to CMV replication (46, 47) . It is therefore possible that tissue expression of cytokines/ chemokines is modulated by CMV, representing an autocrine mechanism by which CMV stimulates itself to ensure survival. Whichever the cause, the fact that blocking CMV reactivation with antiviral therapy prevents this abnormal tissue expression strongly supports the hypothesis that CMV is responsible for this late elevation in TNF-␣ mRNA expression.
Whatever the cause of the observed abnormal TNF-␣ transcription, abnormal pulmonary expression of TNF-␣ appears to be injurious. Mice latently infected with MCMV had significantly higher levels of pulmonary fibrosis than non-CMV-infected mice after bacterial sepsis (Fig. 7) . Perhaps White belts indicate the median value. Boxes give the range between quartiles (25th and 75th percentiles). Notched black regions are 95% confidence intervals for the medians, and the dots indicate the full range of the distributions. Because distributions of pulmonary fibrosis scores are nonnormal, nonparametric tests were used to discern differences among study groups at day 21. Post hoc comparisons of pairs of groups were made using the Mann-Whitney-Wilcoxon test (nonparametric t-test). CMV reactivation was related to significant increases in pulmonary fibrosis compared with healthy controls after CLP (p Ͻ .0007). Blocking CMV reactivation with ganciclovir after CLP appeared to prevent this increased level of fibrosis, as fibrosis was significantly lower in GCV-treated mice than in nontreated mice (p Ͻ .0002). more convincing are the CMVϩGCV mice that received ganciclovir after CLP. These mice did not have CMV reactivation, had normal TNF-␣ transcription, and subsequently did not have the degree of pulmonary fibrosis demonstrated by CMVϩ mice undergoing CLP. Taken together, these data suggest that pulmonary fibrosis may be a direct consequence of CMV reactivation, which may be partly mediated by TNF-␣. This hypothesis is supported by current literature. Numerous models have shown that TNF-␣ is a critical mediator of pulmonary fibrosis (48 -51) . In addition to its direct effects, TNF-␣ also stimulates release of secondary fibrogenic cytokines, namely transforming growth factor-␤, PDGF-␣, and PDGF-␤ (30, 31) . Transforming growth factor-␤ has been shown to induce fibroproliferative lung disease (52, 53) . Although we have not yet studied these secondary mediators, we hypothesize that TNF-␣ mRNA expression seen during MCMV reactivation might cause pathology by this mechanism, resulting in pulmonary fibrosis.
Regardless of the specific mechanism, these results very clearly address the issue of pathogen vs. innocent bystander for CMV reactivation. Previously, several studies have linked herpes family virus reactivations in critically ill patients with significantly increased durations of mechanical ventilation or intensive care unit lengths of stay when compared with patients without reactivation (2) (3) (4) (5) 54) . Some of these studies have also suggested a link between viral reactivation and acute respiratory distress syndrome (3, 54) as well as worsened mortality rate following CMV reactivation (2, 4) . We now suspect that reactivated CMV may actually be a pathogen and not simply a surrogate or indicator of severity of critical illness.
These animal data clearly describe a mechanism by which CMV might act as a pulmonary pathogen in critically ill patients. Although this may seem intuitively to be an inconsequential problem, our previous epidemiologic work has shown that latent HCMV is highly prevalent in critically ill patients, putting Ͼ70% of them at risk for reactivation (3) . Indeed, using very conservative techniques, Ն5-25% of those at risk reactivate HCMV during their critical illness (3) . Given the magnitude of latent HCMV in our critically ill population, therefore, the time has come to move forward in developing strategies for both recognizing and treating this potential pathogen. Fortunately, our data suggest that CMV reactivation may be preventable with antiviral therapy. Studies to address timing of administration as well as alternate dosing regimens of antivirals are ongoing, which should facilitate taking these novel findings back to the bedside.
CONCLUSIONS
Cytomegalovirus reactivation in the immunocompetent host causes abnormal pulmonary tissue expression of numerous cytokines/chemokines. These cytokines/chemokines likely cause the resultant pulmonary fibrosis seen following CMV reactivation. Fortunately, treatment with ganciclovir prevents CMV reactivation following bacterial sepsis, preventing abnormal cytokine/chemokine transcription, thus preventing pulmonary fibrosis. Taken together, these data describe a mechanism by which CMV reactivation may cause lung injury in critically ill patients. Further study using antiviral therapy in critically ill humans is thus warranted.
T his study shows that cytomegalovirus reactivation causes abnormal tumor necrosis factor-␣ expression, and that following cytomegalovirus reactivation, immunocompetent mice have abnormal pulmonary fibrosis.
